Additional Cervical Cancer Testing Information from Cytyc



Overview Clinical Trials Overview Clinical Outcome Trial HSIL+ Other Clinical Studies International Studies Additional Testing Cost Effectiveness Bibliography Additional Testing The ThinPrep® Pap Test is approved by the U.S. Food and Drug Administration (FDA) as a platform for HPV DNA testing directly from the ThinPrep collection vial. A study conducted by the National Cancer Institute concluded that HPV testing is a viable method for determining which patients with borderline Pap results are at highest risk for developing cancer. The ThinPrep method is also approved for Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) testing directly from the ThinPrep Pap Test collection vial using Roche Diagnostics Corporation's COBAS AMPLICOR™ automated system and Gen-Probe's APTIMA COMBO 2® CT/NG assay. ASC-US Management Strategies^1-4 The preferred approach when liquid-based cytology is used. ^2-4 ASC-US Management ¹ Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299. ² Richart R (moderator), Cox J, Twiggs L, Wilkinson E, Wright T. A sea change in diagnosing and managing HPV and cervical cancer - Part 1 (symposium). Contemporary Ob/Gyn. 2002;47:42-44, 47-48, 51-52, 54, 56. ³ Wright T, Cox J, Massad LS, Twiggs L, Wilkinson E. 2001 consensus guidelines for the management of women with cervical abnormalities. JAMA. 2002;287:2120-2129. ⁴ Manos MM, et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610. For additional information on ASC-US management, please see ASCCP "Algorithms from the Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities."